Abstract B113: Discovery of PRT3789, a First-in-class Potent and Selective SMARCA2 Degrader in Clinical Trials for the Treatment of Patients with SMARCA4 Mutated Cancers Koichi Ito , Michael Hulse , Anjana Agarwal , Jack Carter , Monisha Sivakumar , Komali Vykuntam , Min Wang , Miles Cowart , Joy Cote , William Gowen-MacDonald , Brian Vidal Torres , Justin Kurian , Neha Bhagwat , Norman Fultang , Alexander Grego , Andrew Moore , Ashley Schwab , Jessica Burtell , Olusola Peace Osinubi , Jacob Spruance , Liang Lu , Philip Pitis , Corey Basch , Klare Bersch , Chaofeng Dai , Raul Leal , Artem Shvartsbart , Ganfeng Cao , Bo Shen , Patrick Wen , Joseph Rager , Ross Kuskovsky , Bob Landman , Tom Emm , Stefan Ruepp , Chunhua Qin , Gina Paris , Jennifer Xavier , Rachel Chiaverelli , Sang Hyun Lee , Sandy Geeganage , Hong Lin , Diane Heiser , Bruce Ruggeri , Naveen Babbar , Andrew Combs , Peggy Scherle Molecular Cancer Therapeutics（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
